Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Intellia Therapeutics's gross margin for the twelve months ending Dec 31, 2019 was 100.0%. For fiscal 2021 it was 100.0%, against 100.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 100.0% | +0.0 |
| FY2020 | Dec 31, 2020 | 100.0% | +0.0 |
| FY2019 | Dec 31, 2019 | 100.0% | +0.0 |
| FY2018 | Dec 31, 2018 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | 100.0% | +0.0 |
| Q3 FY2019 | Sep 30, 2019 | 100.0% | +0.0 |
| Q2 FY2019 | Jun 30, 2019 | 100.0% | – |
| Q1 FY2019 | Mar 31, 2019 | 100.0% | – |
| Q4 FY2018 | Dec 31, 2018 | 100.0% | – |
| Q3 FY2018 | Sep 30, 2018 | 100.0% | – |
See a number that looks wrong?